C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Stefanie Aeppli,Eric Innocents Eboulet,Tim Eisen,Bernard Escudier,Stefanie Fischer,James Larkin,Viktor Gruenwald,David F. McDermott,Jan Oldenburg,Aurelius Omlin,Camillo Porta,Brian I. Rini,Manuela Schmidinger,Cora N. Sternberg,Christian Rothermundt +14 more
TL;DR: In this paper, the authors performed an online survey among physicians involved in the treatment of metastatic clear cell renal cell carcinoma (mccRCC) patients and 41 experts responded to questions focused on criteria relevant for treatment decision outside the pandemic and the modifications of systemic therapy during COVID-19.
Journal ArticleDOI
TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.
Petros Grivas,Scott T. Tagawa,Joaquim Bellmunt,Maria De Santis,Ignacio Duran,P. J. Goebell,Andrea Necchi,Srikala S. Sridhar,Cora N. Sternberg,M Usman Aziz,Cabilia C. Pichardo,Yohann Loriot +11 more
TL;DR: Patients with locally advanced unresectable or metastatic urothelial carcinoma who progress following prior platinum-based and checkpoint therapies are urged to consider a second line therapy.
Journal ArticleDOI
Common germline-somatic variant interactions in advanced urothelial cancer
Aram Vosoughi,Tuo Zhang,Tuo Zhang,Kyrillus S. Shohdy,Kyrillus S. Shohdy,Panagiotis J. Vlachostergios,David Wilkes,Bhavneet Bhinder,Bhavneet Bhinder,Scott T. Tagawa,David M. Nanus,Ana M. Molina,Himisha Beltran,Cora N. Sternberg,Samaneh Motanagh,Brian D. Robinson,Jenny Xiang,Xiao Fan,Wendy K. Chung,Mark A. Rubin,Olivier Elemento,Olivier Elemento,Andrea Sboner,Andrea Sboner,Juan Miguel Mosquera,Juan Miguel Mosquera,Bishoy Faltas,Bishoy Faltas +27 more
TL;DR: It is shown that UC patients harbor a high prevalence of putative deleterious germline variants that truncate tumor suppressor proteins, suggesting a critical role for these pGVs in tumor progression.
Journal ArticleDOI
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study
Luigi Celio,Cora N. Sternberg,R. Labianca,I. La Torre,Vito Amoroso,C. Barone,Graziella Pinotti,Stefano Cascinu,F. Di Costanzo,Gianluigi Cetto,Emilio Bajetta +10 more
TL;DR: PEMOX is active and well tolerated in AGC and RR, TTP, and survival were comparable to those achieved in studies using different 5-fluorouracil (5-FU)-oxaliplatin combinations, without the inconvenience of prolonged 5-FU schedules.
Journal ArticleDOI
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Andrew J. Armstrong,Ping Lin,Celestia S. Higano,Peter Iversen,Cora N. Sternberg,Bertrand Tombal,De Phung,Teresa Parli,Andrew Krivoshik,Tomasz M. Beer +9 more
TL;DR: It is reported that decreases in PSA levels are closely linked to better health and survival after 3mo of enzalutamide treatment in men with metastatic prostate cancer and was strongly associated with better clinical and patient-reported outcomes.